LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

Search

Iovance Biotherapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

1.75

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.73

Max

1.78

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-38M

-116M

Pardavimai

-24M

49M

Pelnas, tenkantis vienai akcijai

-0.36

Pelno marža

-235.51

Darbuotojai

838

EBITDA

-35M

-110M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+555.68% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-07

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-558M

611M

Ankstesnė atidarymo kaina

1.75

Ankstesnė uždarymo kaina

1.75

Naujienos nuotaikos

By Acuity

50%

50%

174 / 382 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Iovance Biotherapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-05-22 23:48; UTC

Karštos akcijos

Stocks to Watch: Deckers Outdoor, Intuit, Ross Stores, Lightbridge, NuScale Power, Centrus Energy

2025-05-22 23:07; UTC

Svarbiausios naujienos

Fortescue Energy CEO to Resign in Executive Overhaul

2025-05-22 23:03; UTC

Pagrindinės rinkos jėgos

Nuclear-Industry Stocks Get Boost After Report Says Trump Will Sign Orders to Jumpstart Field

2025-05-22 23:59; UTC

Rinkos pokalbiai

Gold Edges Higher, Supported by Lingering Worries Over U.S. Deficits -- Market Talk

2025-05-22 23:45; UTC

Rinkos pokalbiai

Nikkei May Trade in Range as Uncertainty Over Tariffs Continues -- Market Talk

2025-05-22 23:45; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-05-22 23:23; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2025-05-22 23:23; UTC

Rinkos pokalbiai

Fortescue Iron Bridge Delay Disappoints; Executive Changes Welcomed -- Market Talk

2025-05-22 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-05-22 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-05-22 20:46; UTC

Įsigijimai, susijungimai, perėmimai

Alcon and Lensar Receive FTC Requests for Additional Information About Merger

2025-05-22 20:39; UTC

Uždarbis

Tesla's Emissions Credits Are at Risk After Senate's California Vote -- Barrons.com

2025-05-22 20:36; UTC

Svarbiausios naujienos

Antitrust Cops Say BlackRock, Other Fund Giants May Have Harmed Energy Competition -- 4th Update

2025-05-22 20:36; UTC

Svarbiausios naujienos
Uždarbis

Workday Logs Higher 1Q Revenue, Backs Outlook; Initiates $1B Buyback Program

2025-05-22 20:32; UTC

Svarbiausios naujienos
Uždarbis

Intuit Stock Rises After Earnings Grew More than Expected In Latest Tax Season -- Barrons.com

2025-05-22 20:27; UTC

Svarbiausios naujienos

Trump's 'Big, Beautiful Bill' Heads to Senate, Where New Fights Loom -- WSJ

2025-05-22 20:20; UTC

Svarbiausios naujienos

Bond Market Shows Signs of Stabilizing; Nasdaq Rises -- WSJ

2025-05-22 20:17; UTC

Svarbiausios naujienos

The Deficit Is Unsettling Bond Traders. Here's How That Affects the Economy. -- 2nd Update

2025-05-22 20:16; UTC

Uždarbis

Intchains Group 1Q Rev $18.2M >ICG

2025-05-22 20:15; UTC

Svarbiausios naujienos

Bond Market Shows Signs of Stabilizing; Nasdaq Rises -- WSJ

2025-05-22 20:08; UTC

Svarbiausios naujienos
Uždarbis

Intuit Stock Rises After Earnings Grew More than Expected In Latest Tax Season -- Barrons.com

2025-05-22 20:05; UTC

Svarbiausios naujienos

Intuit Seeing Stable Environment for Consumers, Businesses While Tariffs Play Out

2025-05-22 20:04; UTC

Uždarbis

Workday Sees FY26 Subscription Revenue $8.8B >WDAY

2025-05-22 20:04; UTC

Uždarbis

Workday Sees 2Q Subscription Revenue $2.16B >WDAY

2025-05-22 20:01; UTC

Uždarbis

Intuit Sees FY25 EPS $13.19-EPS $12.24 >INTU

2025-05-22 20:01; UTC

Uždarbis

Workday 1Q Net $68M >WDAY

2025-05-22 20:01; UTC

Uždarbis

Workday 1Q EPS 25c >WDAY

2025-05-22 20:01; UTC

Uždarbis

Workday 1Q Adj EPS $2.23 >WDAY

2025-05-22 20:01; UTC

Uždarbis

Workday 1Q Subscription Revenue $2.06B >WDAY

2025-05-22 20:01; UTC

Uždarbis

Workday 1Q Rev $2.24B >WDAY

Akcijų palyginimas

Kainos pokytis

Iovance Biotherapeutics Inc Prognozė

Kainos tikslas

By TipRanks

555.68% į viršų

12 mėnesių prognozė

Vidutinis 11.54 USD  555.68%

Aukščiausias 25 USD

Žemiausias 2 USD

Remiantis 15 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Iovance Biotherapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

15 ratings

9

Pirkti

6

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

3.0208 / 3.5Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Rinkos nuotaikos

By Acuity

174 / 382 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Iovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.